Blood Products

Our in­novative blood operations and manufacturing practices establish NYBC as a leading Center of Excellence in blood product and service delivery. We continue to enhance our abil­ity to provide the highest quality products and the best level of service to the patients and hospitals that depend on us. 

NYBC is dedicated to providing the highest quality blood products and services. Our staff is ready to serve you 24/7.

  • Red Blood Cells

    Red blood cells (RBCs) are important for delivering oxygen to our bodies’ tissues. RBCs are the component of choice for patients with a symptomatic deficit of oxygen-carrying capacity due to low hemoglobin/hematocrit. They may also be used to help restore cells lost following significant hemorrhage due to trauma, during and after significant surgery, or during a difficult birth. RBCs, or packed red blood cell units, are prepared from donated whole blood or collected by apheresis. The majority of NYBC’s RBCs are stored in an additive solution that allows for a 42-day shelf life. RBC unit modification includes:


    Leukoreduced RBCs have been filtered to remove the majority of the white blood cells (leukocytes). This product reduces the risk of febrile nonhemolytic transfusion reactions, HLA alloimmunization, and cytomegalovirus (CMV) transmission. Leukoreduced RBCs are considered CMV-safe. All NYBC RBC products are leukoreduced. Leukoreduced RBCs are offered in two configurations: single standard bag alone or two or four pediatric packs attached.


    RBC units are irradiated to inactivate lymphocytes to prevent transfusion-associated-graft-versus-host disease, which is a rare yet serious outcome of transfusion due to donor lymphocyte engraftment into a recipient. At highest risk for this complication are those who have: congenital immunodeficiencies; hematologic malignancies; are treated with drugs that affect T cell number or function; receive hematopoietic stem cell transplants; and those receiving intrauterine transfusion products from relatives, HLA matched products, and granulocytes. Potassium levels may increase at rates higher than seen in non-irradiated red cells. The timing between irradiation and transfusion may need to be considered in patients at risk of high potassium levels.


    RBC units that have been frozen and subsequently deglycerolized are similar in function to liquid stored RBCs. A unit contains at least 80% of the original RBCs following the deglycerolization process. Virtually all plasma, platelets, and most leukocytes are removed from the unit. The frozen blood inventory is a source of rare blood cells. Frozen storage is also useful for the storage of autologous RBCs beyond the time limits of liquid storage for patients with complex RBC transfusion needs and cancellation or rescheduled surgery.


    Washing a RBC unit with sterile, normal saline removes about 99% of the non-cellular fluid in a unit of blood, including plasma proteins, electrolytes, and antibodies. Saline washed RBCs are indicated for patients with a history of severe allergic reactions.


    These RBC units are from donors tested and found negative for past exposure to cytomegalovirus (CMV). CMV seronegative products are CMV-safe, like leukoreduced products, and are used to mitigate the risk of transfusion-transmitted CMV. Patients at risk include CMV-negative recipients of hematopoietic stem cell or solid organ transplants and premature infants whose mothers are CMV seronegative.


    These RBCs are from donors who have been tested for the hemoglobin S variant (Hgb S) responsible for sickle cell disease. Indications for transfusion of Hgb S negative RBCs include patients with sickle cell disease, fetuses, and infants.


    See Immunohematology

  • Plasma Products

    Frozen plasma products include fresh frozen plasma (FFP), which is separated and frozen within 8 hours of collection, or plasma frozen within 24 hours of collection (FP24). Both contain plasma proteins and coagulation factors and can be used interchangeably (FP24 has a slight decrease in factor VII and V activities). These products can be thawed and stored in the refrigerator for 5 days (termed thawed plasma). These products are used in the management of preoperative or bleeding patients who require replacement of multiple plasma coagulation factors or when factor concentrates are not available, such as in liver disease, disseminated intravascular coagulopathy (DIC), thrombotic thrombocytopenic purpura (TTP), or immediate warfarin reversal.


    Cryoprecipitate reduced plasma is made from FFP after cryoprecipitate has been removed. The single indication for this product is TTP.


    Each cryoprecipitate unit contains at least 80 units of Factor VIII and 150 mg of fibrinogen in less than 15 ml of plasma. Cryoprecipitate also contains von Willebrand factor, factor XIII, and fibronectin.  A pre-pool of 5 cryoprecipitate units is available. Cryoprecipitate is used primarily for the prevention or control of bleeding associated with fibrinogen deficiency.


    New York Blood Center is pleased to announce distribution of a new plasma product: Octaplas.  This product from Octapharma USA is a solvent/detergent treated, pooled human plasma for intravenous use only. It is indicated for replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or undergoing cardiac surgery or liver transplantations, and in plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP).

    Product Overview

    • Octaplas is supplied in 200 mL bags
    • Octaplas is a sterile, pyrogen free, frozen solution of solvent/detergent (S/D) treated pooled human plasma and is manufactured from human plasma collected in US licensed plasma donation centers
    • All plasma donations are tested for viral markers in compliance with US regulations
    • Each lot is manufactured from pooled plasma of a single ABO group (A, B, AB or O)
    • The pool is limited to 390kg comprising 630 – 1,520 individual donors
    • Finished products are tested for coagulation factors II, V, VII, VIII, X and XI, Protein C, Protein S, alpha2-antiplasmin (also known as Plasmin Inhibitor), fibrinogen and ADAMTS13.
    • The S/D treatment step has been validated to effectively inactivate relevant pathogenic and model enveloped viruses including HIV-1, PRV, SBV and BVDV.

    Dosage and Administration

    Octaplas is administered based on ABO-blood group compatability for replacement of coagulation factors in patients with acquired deficiencies due to liver disease or undergoing cardiac surgery or liver transplant.

    Initially infuse 10 to 15 mL of Octaplas per kilogram of bodyweight.  This should increase the patient’s plasma coagulation factor levels by approximately 15-25%.  If hemostasis is not achieved, use higher doses.

    Octaplas Package Insert

  • Platelet Products

    Platelet products are either manufactured from: apheresis collections, also known as single donor platelets (SDP), plateletapheresis or apheresis platelets; or whole blood derived platelet concentrates. Five units of whole blood derived platelet concentrates are pooled together before storage to make a therapeutic platelet dose. All NYBC platelet products are tested for bacterial contamination using a culture system. 

    • NYBC platelet products are all leukoreduced.
    • CMV seronegative platelets can be ordered.
    • Platelet products can be washed to remove plasma.
    • Platelet products can be irradiated.
    • HLA matched or crossmatched platelets may be needed to treat patients with post-transfusion platelet refractoriness, when their platelet count does not adequately rise after a platelet transfusion due to HLA and/or platelet antibodies. 
    • Platelet products collected and stored in platelet additive solution (PAS) are available. PAS decreases risk of allergic reactions.

    Acrodose Whole Blood Derived Platelets Brochure

  • Frozen Blood and Washed Products

    NYBC's frozen blood reserves are one of the largest repositories in the U.S. Frozen red cells are an excellent resource for patients with rare or uncommon blood types. The laboratory, with Daisy Charles-Pierre MT(ASCP)BB as Manager, provides washed red blood cells (RBCs) and platelets, storage of autologous units, and frozen units for rare and uncommon blood types. These can be unique to a specific ethnic background.

    NYBC maintains frozen reserves as FDA licensed products. Blood can be frozen and stored up to 10 years, but must be transfused within 24 hours of thawing. Frozen units can be shipped anywhere in the U.S., subject to prevailing regulations.


    Washed RBCs and Platelets

    •   The preferred component for patients sensitized to immunoglobulin A (IgA).
    •   May also be indicated for patients sensitized to leukocyte and platelet antigens

    Autologous Donation and Frozen Storage

    • Indicated for patients with very rare blood group phenotypes
    • Frozen services are also available to store autologous blood for patients who have had surgery postponed
    • For patients with potential need for transfusion beyond the maximum storage time available for liquid blood
    • Autologous blood units are kept frozen for up to six months unless the blood is very rare, or by special request
    • Frozen-thawed red cells for rare and uncommon blood types


  • Whole Blood

    Whole blood contains approximately 500 ml of anticoagulated whole blood. The platelets are non-viable after a few days. Levels of labile clotting factors decline with storage. Whole blood provides oxygen-carrying capacity and blood volume expansion and may be useful in bleeding patients who have lost in excess of 20% of total blood volume. Patients with chronic anemia who have a normal blood volume should receive red blood cells.

  • Granulocytes

    Granulocyte products are collected through apheresis. Granulocyte products contain >1 x 1010 granulocytes, 10-30 ml of RBCs, and 1-6x1010 platelets. Granulocytes should be irradiated and transfused within 12-24 hours after collection. Granulocyte transfusions are indicated for patients who are severely neutorpenic or have a neutrophil function defect.

    Granulocyte Product Request Form

  • Autologous and Directed Blood Donation

    Autologous blood donation is a process by which, before your upcoming surgery, you can donate your own blood to be used for transfusion. You can donate one unit of blood per week in advance of your surgery, but special medical circumstances may allow more frequent donations if your physician and a NYBC Medical Director deem necessary. If your scheduled surgery is delayed for any reason, your blood may be preserved as a frozen unit until your next surgery date becomes available. Autologous blood donations require special handling, and at least five business days are needed to test, process, and ship the blood to your surgery location. There is a special handling fee charged to cover the cost of this service.


    Directed blood donation is a donation in which the recipient chooses the donor.  It is also an alternate way of having the desired amount of blood for surgery if you are not able to donate your own blood by reason of physical or medical restrictions. In a directed donation, the recipient chooses the donor, usually a family member or friend who then donates specifically for that recipient. Studies have shown that blood from directed donors is no safer than blood from the volunteer blood supply. As with autologous donations, a directed donation requires special handling and at least five business days are needed to test, process, and ship the blood to the recipient’s location. There is a special handling fee charged to cover the cost of this service.

    Learn more about the different types of donations you can make.

  • HEMACORD® (HPC, Cord Blood)

    We are pleased to announce the availability of HEMACORD® (HPC, Cord Blood), the first FDA approved allogeneic cord-blood derived hematopoietic stem cell therapy product.

Contact A Customer Relations Manager

If you are a blood donor and need customer service, contact NYBC here.